Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients.

Sączek A, Batko K, Banaszkiewicz M, Małyszko J, Koc-Żórawska E, Żórawski M, Niezabitowska K, Sobczyńska K, Miarka P, Bętkowska-Prokop A, Krzanowska K, Krzanowski M

Kidney & blood pressure research21 May 2026

PMID42166398PMCIDPMC13395389DOI10.1159/000552202PepBankPUB-42166398

Read at source PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
Median serum MOTS‑c was significantly higher in kidney transplant recipients than in controls.
In plain wordsKidney transplant recipients had higher levels of the body's own MOTS‑c in blood than controls.
Peptide
MOTS-c
Outcome
IncreaseSerum MOTS-c in kidney transplant recipients versus controls
Study
n = 150
Comparator
Controls
Outcome group
Aging markers · Kidney and urinary
Measurements
Median serum MOTS-c
178 ng/mL
kidney transplant recipients
Median serum MOTS-c
142 ng/mL
controls
Source sentences
Summary
and MOTS-c (178 vs. 142 ng/mL, p = 0.014) were significantly higher in KTRs, as compared with controls
1 context sentence(design, population, supporting numbers)
Summary · context
We measured serum NRDc and MOTS-c concentrations in an observational cohort of 150 patients (118 KTRs and aged-matched controls - 32 patients) using commercial ELISA kits.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4216639801
02HumanEndogenous levelObservational studyOther
Serum MOTS‑c showed no significant associations with cardiometabolic features.
In plain wordsNatural MOTS‑c levels in blood were not significantly linked to heart or metabolic features.
Peptide
MOTS-c
Outcome
No significant changeSerum MOTS-c and cardiometabolic features
Study
n = 150
Outcome group
Cardiovascular events · Kidney and urinary
Source sentences
Summary
We did not observe significant associations for MOTS-c and cardiometabolic features.
1 context sentence(design, population, supporting numbers)
Summary · context
We measured serum NRDc and MOTS-c concentrations in an observational cohort of 150 patients (118 KTRs and aged-matched controls - 32 patients) using commercial ELISA kits.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4216639802
03HumanEndogenous levelObservational studyOther
Serum MOTS‑c showed a consistent but nonsignificant trend toward lower risk of allograft loss.
In plain wordsHigher natural MOTS‑c in blood was not significantly linked to graft loss, though the trend pointed to lower risk.
Peptide
MOTS-c
Outcome
No significant changeSerum MOTS-c and renal allograft loss
Study
n = 118
Outcome group
Cardiovascular events · Kidney and urinary
Measurements
Adjusted sHR
0.5
allograft loss
Source sentences
Summary
In competing risk analysis, MOTS-c showed a consistent but nonsignificant trend toward lower risk of allograft loss (adj. sHR 0.50, 95% CI: 0.22-1.10, p = 0.08)
1 context sentence(design, population, supporting numbers)
Summary · context
We measured serum NRDc and MOTS-c concentrations in an observational cohort of 150 patients (118 KTRs and aged-matched controls - 32 patients) using commercial ELISA kits.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4216639803
04HumanEndogenous levelObservational studyOther
Serum MOTS‑c was not associated with all-cause mortality.
In plain wordsNatural MOTS‑c levels in blood were not linked to death from any cause.
Peptide
MOTS-c
Outcome
No significant changeSerum MOTS-c and all-cause mortality
Study
n = 118
Outcome group
Cardiovascular events · Kidney and urinary
Source sentences
Summary
Both serum NRDc and MOTS-c markers were not associated with all-cause mortality or follow-up eGFR decline.
1 context sentence(design, population, supporting numbers)
Summary · context
We measured serum NRDc and MOTS-c concentrations in an observational cohort of 150 patients (118 KTRs and aged-matched controls - 32 patients) using commercial ELISA kits.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4216639804
05HumanEndogenous levelObservational studyOther
Serum MOTS‑c was not associated with follow-up eGFR decline.
In plain wordsNatural MOTS‑c levels in blood were not linked to a drop in kidney function over follow-up.
Peptide
MOTS-c
Outcome
No significant changeSerum MOTS-c and follow-up eGFR decline
Study
n = 118
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Both serum NRDc and MOTS-c markers were not associated with all-cause mortality or follow-up eGFR decline.
1 context sentence(design, population, supporting numbers)
Summary · context
We measured serum NRDc and MOTS-c concentrations in an observational cohort of 150 patients (118 KTRs and aged-matched controls - 32 patients) using commercial ELISA kits.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4216639805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.